Recursion Pharmaceuticals (RXRX) just unveiled an update.
Recursion Pharmaceuticals, Inc. has expanded its Board of Directors to nine members, welcoming Najat Khan, Ph.D., as a new Class II Director, with her term running until the 2026 Annual Meeting of Stockholders. Starting April 16, 2024, Dr. Khan will also serve as the company’s Chief Research and Development Officer and Chief Commercial Officer. Her compensation includes a significant base salary, bonus potential, and a substantial initial equity grant, along with a sign-on bonus, all while not receiving extra pay for her director role. Dr. Khan’s appointment follows a direct offer from the company without any disclosed related party transactions.
For a thorough assessment of RXRX stock, go to TipRanks’ Stock Analysis page.
